DaVita Inc. (DVA)

58.80
2.75 4.91
NYSE : Health Services
Prev Close 56.05
Open 59.31
Day Low/High 58.40 / 59.89
52 Wk Low/High 43.40 / 79.11
Volume 5.90M
Avg Volume 1.78M
Exchange NYSE
Shares Outstanding 166.40M
Market Cap 9.44B
EPS 0.90
P/E Ratio 17.25
Div & Yield N.A. (N.A)

Latest News

DaVita Inc. Announces Preliminary Second Quarter 2019 Results And Updated Guidance For Fiscal Year 2019

DaVita Inc. Announces Preliminary Second Quarter 2019 Results And Updated Guidance For Fiscal Year 2019

DENVER, July 22, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita" or "Company"), today announced preliminary second quarter 2019 financial and operating results and updated guidance for fiscal year 2019.

DaVita Inc. Schedules 2nd Quarter 2019 Investor Conference Call

DaVita Inc. Schedules 2nd Quarter 2019 Investor Conference Call

DENVER, July 22, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States and in 9 countries around the world, announced today that it will hold its quarterly conference call to discuss second quarter...

DaVita Statement On Advancing American Kidney Health

DaVita Statement On Advancing American Kidney Health

DENVER, July 10, 2019 /PRNewswire/ --  DaVita Kidney Care appreciates President Trump, the Administration and Secretary Azar for taking steps to improve the lives of kidney patients.

DaVita Continues To Transform Patient Care, Pushes For Continued Innovation In Kidney Care

DaVita Continues To Transform Patient Care, Pushes For Continued Innovation In Kidney Care

Affirms commitment to value-based kidney care and improving kidney disease prevention, home dialysis and transplantation

Looking for Winners of a Potential Healthcare Policy Proposal

Two companies that could benefit are CVS Health and UnitedHealth Group.

DaVita Lower as HHS Plans to Emphasize At-Home Dialysis Treatment

DaVita Lower as HHS Plans to Emphasize At-Home Dialysis Treatment

A looming federal health-care shift has the potential to shake up the $24 billion dialysis industry, in which DaVita is a leading player.

Harvest One Completes Acquisition Of Delivra

Harvest One Completes Acquisition Of Delivra

TORONTO, July 3, 2019 /PRNewswire/ - Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF - " Harvest One") and Delivra Corp.

Harvest One And Delivra Provide Update On Closing Date Of Transaction

Harvest One And Delivra Provide Update On Closing Date Of Transaction

VANCOUVER, June 28, 2019 /PRNewswire/ - Harvest One Cannabis Inc. (" Harvest One") (TSXV: HVT; OTCQX: HRVOF) and Delivra Corp.

Optum Completes Acquisition Of DaVita Medical Group From DaVita

Optum Completes Acquisition Of DaVita Medical Group From DaVita

Optum, a leading health services company, completed its acquisition of DaVita Medical Group, one of the nation's leading independent medical groups, from DaVita Inc.

Buffett's Berkshire Hathaway Closes Below $300,000

Buffett's Berkshire Hathaway Closes Below $300,000

Shares of Warren Buffett's investment vehicle, Berkshire Hathaway, ended the day below $300,000 for the first time since late March.

Buy-Write Magic With DaVita

Buy-Write Magic With DaVita

Buy-write combinations are a very powerful investment technique.

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How DaVita Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that DaVita Inc is the #43 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

DaVita Reports On 2018 Corporate Social Responsibility Initiatives

DaVita Reports On 2018 Corporate Social Responsibility Initiatives

Company highlights achievements in patient care, community growth and sustainability

DaVita Inc. 1st Quarter 2019 Results

DaVita Inc. 1st Quarter 2019 Results

DENVER, May 7, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced results for the quarter ended March 31, 2019.

DaVita Expected to Earn 93 Cents a Share

DaVita Expected to Earn 93 Cents a Share

DaVita revenue expected to fall 1.2% to $2.8 billion.

DaVita Announces CEO Succession

DaVita Announces CEO Succession

Javier J. Rodriguez named CEO effective June 1, 2019; Kent J. Thiry to serve as Executive Chairman of the board of directors

DAVITA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of DaVita Inc. - DVA

DAVITA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of DaVita Inc. - DVA

NEW ORLEANS, April 26, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

DaVita Inc. Schedules 1st Quarter 2019 Investor Conference Call

DaVita Inc. Schedules 1st Quarter 2019 Investor Conference Call

DENVER, April 26, 2019 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States and in 10 countries around the world, announced today that it will hold its quarterly conference call to discuss first quarter...

The New #158 Most Shorted S&P 500 Component: DaVita

The New #158 Most Shorted S&P 500 Component: DaVita

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

DaVita To Use 100 Percent Renewable Energy

DaVita To Use 100 Percent Renewable Energy

Company enters into virtual power purchase agreements

Helping Patients Along Their Kidney Transplant Journey

Helping Patients Along Their Kidney Transplant Journey

DaVita launches education and support program to help patients pursue a kidney transplant

DaVita Launches Health Tour In California To Provide Health Screenings And Kidney Education

DaVita Launches Health Tour In California To Provide Health Screenings And Kidney Education

LOS ANGELES, April 23, 2019 /PRNewswire/ -- DaVita Kidney Care, a division of DaVita Inc.

Buffett's 'Big Mistake' Is Finally Looking Up

Buffett's 'Big Mistake' Is Finally Looking Up

Warren Buffett's big bet on kidney dialysis provider DaVita may finally be primed to start paying off, albeit after five frustrating years of negative returns.

Lifshitz & Miller LLP Announces Investigation Of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., And Uniti Financial Corporation

Lifshitz & Miller LLP Announces Investigation Of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., And Uniti Financial Corporation

NEW YORK, April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc.

TheStreet Quant Rating: C+ (Hold)